Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Hyper-CVAD for Burkitt's Leukemia/Lymphoma
NCT00669877Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2002
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Burkitt lymphoma (BL) and Burkitt-like lymphoma (BLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission Rate. Started Aug 2002; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt-like lymphoma (BLL)
Beyond the preview
Go deeper on NCT00669877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669877.